ReviewFrontiers in immunology2022
Cardiovascular Disease in Primary Sjögren's Syndrome: Raising Clinicians' Awareness.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Comparison of cardiac MRI features of fibrosis and strain for early cardiac dysfunction assessment in patients with systemic lupus erythematosus and Sjögren's syndrome.Lupus science & medicine · 2026Article
- Impact of Inflammatory Disorders on Outcomes in Acute Heart Failure: A Nationwide Analysis.Cardiology · 2026Article
- Impaired pulmonary function associated with subclinical myocardial injury in primary Sjögren's syndrome: a preliminary cardiac magnetic resonance study.Clinical rheumatology · 2026Article
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort.Rheumatology international · 2026Article
- Sjogren's Disease and Elevated Cardiovascular Risk: Mechanisms and Treatment.Journal of cardiovascular development and disease · 2025Review
- Lipid Metabolism: An Emerging Player in Sjögren's Syndrome.Clinical reviews in allergy & immunology · 2025Review
- Distinct characteristics of carpal tunnel syndrome among Sjögren's disease patients and their clinical implications.Reumatologia · 2025Article
- Elevated concentration of beta2-microglobulin among patients with carpal tunnel syndrome in the course of primary Sjögren syndrome - a prospective observational study on 50 patients.Rheumatology international · 2024Observational
- Sjögren's syndrome and Parkinson's Disease: A bidirectional two-sample Mendelian randomization study.PloS one · 2024Observational
- Chronic constrictive pericarditis: a rare cardiac involvement in primary Sjögren's syndrome.BMC cardiovascular disorders · 2023Article
- Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren's Syndrome.Biomolecules · 2023Article
- The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.Journal of personalized medicine · 2023Review
- Review
- Comparative Analysis of Hematological and Immunological Parameters in Patients with Primary Sjögren's Syndrome and Peripheral Neuropathy.Journal of clinical medicine · 2023Article
- Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the ever evolving landscape of systemic immune mediated diseases, an increased awareness regarding the associated cardiovascular system impairment has been noted in recent years. Even though primary Sjögren's Syndrome (pSS) is one of the most frequent autoimmune diseases affecting middle-aged individuals, the cardiovascular profile of this specific population is far less studied, at least compared to other autoimmune diseases. Traditional cardiovascular risk factors and disease specific risk factors are inextricably intertwined in this particular case. Therefore, the cardiovascular risk profile in pSS is a multifaceted issue, sometimes difficult to assess. Furthermore, in the era of multimodality imaging, the diagnosis of subclinical myocardial and vascular damage is possible, with recent data pointing that the prevalence of such involvement is higher in pSS than in the general population. Nevertheless, when approaching patients with pSS in terms of cardiovascular diseases, clinicians are often faced with the difficult task of translating data from the literature into their everyday practice. The present review aims to synthesize the existing evidence on pSS associated cardiovascular changes in a clinically relevant manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.